Haines et al. demonstrated that IK-595, compared to other MEK/RAF inhibitors, can inhibit MEK and ERK1/2 phosphorylation for a longer duration in RAS-mutant cancer models, achieving prolonged target engagement and pathway inhibition. This evidence concerns the gene MAP2K7 and cancer.